What is CraniUS?
CraniUS Therapeutics operates at the intersection of advanced medical engineering and neurology. The company is primarily recognized for its development of the NeuroPASS platform, a sophisticated implantable device engineered to circumvent the blood-brain barrier. By facilitating direct drug delivery, CraniUS addresses critical gaps in the treatment of debilitating conditions, including glioblastoma, Alzheimer disease, and Parkinson disease. Its market position is defined by a focus on high-barrier-to-entry medical devices that require rigorous clinical validation and long-term strategic development.
How much funding has CraniUS raised?
CraniUS has raised a total of $39.4M across 2 funding rounds:
Series A
$19.4M
Series B
$20M
Series A (2022): $19.4M, investors not publicly disclosed
Series B (2026): $20M led by State of Maryland
Key Investors in CraniUS
State of Maryland
The State of Maryland acts as a public sector stakeholder, providing economic development support and infrastructure investment to foster innovation within the regional biotechnology and medical device corridor.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CraniUS?
Following this major enterprise-level funding, CraniUS is positioned to accelerate its clinical development pipeline and scale its manufacturing capabilities. The strategic deployment of this capital will likely focus on advancing the NeuroPASS platform through subsequent regulatory phases and expanding its research footprint. As the company transitions from early-stage innovation to a more mature operational phase, the focus will shift toward establishing commercial viability and securing partnerships with major pharmaceutical entities to integrate their proprietary treatments into the CraniUS delivery ecosystem.
See full CraniUS company page
